UBS has initiated coverage on Zydus Lifesciences Ltd. and Dr Reddy’s Laboratories Ltd. with a ‘Sell’ recommendation, setting price targets of ₹850 and ₹5,700 per share, respectively, citing that the market is overestimating their core margins.
UBS has initiated coverage on Zydus Lifesciences Ltd. and Dr Reddy’s Laboratories Ltd. with a ‘Sell’ recommendation, setting price targets of ₹850 and ₹5,700 per share, respectively, citing that the market is overestimating their core margins.